Brain Metastases
Conditions
Keywords
brain metastases
Brief summary
This study will investigate the safety, tolerability, and effectiveness of changing the order of receiving radiation therapy for treating brain cancer. The investigators hope that changing the sequence of radiation therapy will lower the risk of cancer spreading throughout your spinal fluid, which covers your brain and spinal cord.
Detailed description
This study will attempt to determine the maximum tolerated dose of pre-operative stereotactic radiosurgery (SRS) in the treatment of brain metastases. Patients will be placed in one of two dose groups based on index tumor size, and dose will be adjusted according to presence or absence of dose limiting toxicity (DLT). Group A: Index Tumor \> 2 cm and up to 4 cm in maximum diameter Group B: Index Tumor \> 4 cm and up to 6 cm in maximum diameter Dose escalation or de-escalation will be conducted via a modified 3+3 method at the following levels. Group A will start at dose level II. Group B will start at dose level I. Dose Level I: 12 Gy Dose Level II: 15 Gy
Interventions
RADIATIONStereotactic Radiosurgery (15 Gy)
Group A will start at dose level II: 15 Gy Group B will start at dose level I: 12 Gy
RADIATIONStereotactic Radiosurgery (12 Gy)
Group B will start at Dose Level I: 12 Gy
Sponsors
University of Alabama at Birmingham
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All subjects must have history of histologically confirmed malignancy. Brain biopsy is not required unless diagnosis is judged to be in doubt by the treating physician. * Newly diagnosed brain metastases (four or fewer by post-contrast MRI obtained within six weeks of study entry) * At least one brain metastasis (index tumor) must be within 2-6 cm in maximum diameter and deemed appropriate for surgical resection by the treating neurosurgeon. * Karnofsky performance status (KPS) of greater than or equal to 60 * Age greater than 19 * Life expectancy greater than 12 weeks * Subjects given written informed consent
Exclusion criteria
* Patients with small cell lung cancer and lymphoma are ineligible. * More than four metastases by baseline post-contrast MRI * Prior whole brain radiation therapy * Insufficient recovery from all active toxicities of prior therapies * Subjects who are deemed to be poor surgical risks by the treating neurosurgeon because of medical comorbidities * Pregnant or nursing women * Women of childbearing potential who are not using an effective method of contraception are excluded. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to administration of SRS.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum tolerated dose (MTD) of preoperative stereotactic radiosurgery (SRS) for brain metastasis | one year | The maximum tolerated dose (MTD) is defined as the highest dose of stereotactic radiosurgery delivered pre-operative at which no more than 2 out of 6 patients experience a dose limiting toxicity (DLT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute Toxicity with preoperative stereotactic radiosurgery (SRS) | 6 months | Any possible, probable, or definite treatment-related AE or SAE (assessed by CTCAE 4.0) occurring within six months or less from the date of stereotactic radiosurgery was received. |
| Late Toxicity with preoperative stereotactic radiosurgery (SRS) | 1 year | Any possible, probable, or definite treatment-related AE or SAE (assessed by CTCAE 4.0) occurring more than six months from the date of stereotactic radiosurgery was received. |
| Rates of Local Control | 2 years | This will be assessed by MRI Imaging obtained post-operatively at follow-up visits. |
| Rates of Leptomeningeal Dissemination | 2 years | Leptomeningeal Dissemination (LMD) defined as diffuse carcinomatosis and/or distant focal pachymeningeal (dural) tumor and assessed by MRI Imaging for the study period. |
Countries
United States
Outcome results
None listed